Track Avid Bioservices's operating income ($-20M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Oct 31, 2024
Trailing 12 months ending Oct 31, 2024
As of the most recent data (October 2024), CDMO shows a operating income of $-20M. That compares with $-11M in the prior-year period — down 79.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CDMO's operating income is now $-20M (was $-11M) — a 79.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Avid Bioservices is outperforming or lagging.
Tracking CDMO's operating income over time shows whether Avid Bioservices is scaling, shrinking, or reshaping that part of the business. The current reading is $-20M That compares with $-11M in the prior-year period — down 79.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has Avid Bioservices's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-20M) with ownership activity and broader fundamentals.
Avid Bioservices's operating income is $-20M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.